REXAHN PHARMACEUTICALS INC's ticker is RNN and the CUSIP is 761640101. A total of 1 filers reported holding REXAHN PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $658,000 | +406.2% | 1,290,365 | +40.8% | 0.00% | – |
| Q4 2016 | $130,000 | -32.3% | 916,385 | 0.0% | 0.00% | – |
| Q3 2016 | $192,000 | -16.5% | 916,385 | 0.0% | 0.00% | – |
| Q2 2016 | $230,000 | -23.8% | 916,385 | 0.0% | 0.00% | – |
| Q1 2016 | $302,000 | -9.0% | 916,385 | 0.0% | 0.00% | – |
| Q4 2015 | $332,000 | -30.3% | 916,385 | 0.0% | 0.00% | – |
| Q3 2015 | $476,000 | -14.4% | 916,385 | 0.0% | 0.00% | – |
| Q2 2015 | $556,000 | -16.8% | 916,385 | 0.0% | 0.00% | – |
| Q1 2015 | $668,000 | +4.2% | 916,385 | 0.0% | 0.00% | – |
| Q4 2014 | $641,000 | -13.6% | 916,385 | 0.0% | 0.00% | – |
| Q3 2014 | $742,000 | +19.5% | 916,385 | +28.2% | 0.00% | – |
| Q2 2014 | $621,000 | +13.3% | 714,939 | +40.9% | 0.00% | – |
| Q1 2014 | $548,000 | +288.7% | 507,428 | +83.2% | 0.00% | – |
| Q4 2013 | $141,000 | +12.8% | 276,931 | 0.0% | 0.00% | – |
| Q3 2013 | $125,000 | +15.7% | 276,931 | +14.1% | 0.00% | – |
| Q2 2013 | $108,000 | – | 242,658 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Northeast Financial Consultants Inc | 150,000 | $130,000 | 0.07% |
| Benin Management CORP | 83,000 | $72,000 | 0.04% |
| CONDOR CAPITAL MANAGEMENT | 114,987 | $100,000 | 0.03% |
| FIRST NEW YORK SECURITIES LLC /NY | 15,000 | $13,050,000 | 0.01% |
| Advisory Services Network, LLC | 22,000 | $19,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 180,000 | $157,000 | 0.00% |
| Moors & Cabot, Inc. | 25,000 | $22,000 | 0.00% |
| Corbenic Partners LLC | 1,600 | $1,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 4,566 | $4,000 | 0.00% |
| AQR Capital Management | 213,900 | $186,000 | 0.00% |